Drug Profile


Alternative Names: Fibrostat; Putrescine dihydrochloride

Latest Information Update: 06 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ambrilia Biopharma
  • Developer Ambrilia Biopharma; Biovail Corporation
  • Class Biogenic amines; Diamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Transglutaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertrophic scars

Most Recent Events

  • 03 Mar 2006 Cellpep has merged with Procyon Biopharma to form Ambrilia Biopharma
  • 20 Jan 2005 Data from a media release have been added to the adverse events and Skin disorders therapeutic trials sections
  • 21 Jul 2004 Procyon Biopharma has completed enrolment in a phase IIb trial for Hypertrophic scars in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top